Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPH NASDAQ:HRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$16.04+1.7%$15.08$7.28▼$16.88$2.05B1.441.03 million shs928,327 shsHRTXHeron Therapeutics$1.23+0.8%$0.96$0.74▼$2.61$230.14M1.72.12 million shs1.74 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+4.50%0.00%+2.75%+10.01%+94.19%HRTXHeron Therapeutics-3.15%+1.65%+53.90%-6.82%-42.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$16.04+1.7%$15.08$7.28▼$16.88$2.05B1.441.03 million shs928,327 shsHRTXHeron Therapeutics$1.23+0.8%$0.96$0.74▼$2.61$230.14M1.72.12 million shs1.74 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+4.50%0.00%+2.75%+10.01%+94.19%HRTXHeron Therapeutics-3.15%+1.65%+53.90%-6.82%-42.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 2.50Moderate Buy$17.257.54% UpsideHRTXHeron Therapeutics 2.20Hold$4.50265.85% UpsideCurrent Analyst Ratings BreakdownLatest HRTX and AUPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026AUPHAurinia Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)4/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/21/2026HRTXHeron Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold2/26/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$283.05M7.36$1.03 per share15.56$4.41 per share3.64HRTXHeron Therapeutics$154.90M1.50N/AN/A$0.07 per share17.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$287.20M$2.087.7120.05N/A101.46%27.47%19.61%5/11/2026 (Estimated)HRTXHeron Therapeutics-$20.19M-$0.13N/A10.25N/A-13.04%N/A-4.62%5/11/2026 (Estimated)Latest HRTX and AUPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026AUPHAurinia Pharmaceuticals$0.18N/AN/AN/A$76.98 millionN/A5/11/2026Q1 2026HRTXHeron Therapeutics-$0.03N/AN/AN/A$36.72 millionN/A2/26/2026Q4 2025AUPHAurinia Pharmaceuticals$0.21$1.53+$1.32$1.53$74.70 million$77.11 million2/26/2026Q4 2025HRTXHeron Therapeutics-$0.03-$0.02+$0.01-$0.02$39.53 million$40.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.095.254.76HRTXHeron Therapeutics10.592.481.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%HRTXHeron Therapeutics80.01%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%HRTXHeron Therapeutics5.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300129.94 million114.09 millionOptionableHRTXHeron Therapeutics300188.64 million177.59 millionOptionableHRTX and AUPH HeadlinesRecent News About These CompaniesAnalysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out forMay 4 at 11:00 AM | zacks.comHeron Therapeutics (NASDAQ:HRTX) Downgraded by Zacks Research to "Strong Sell"April 29, 2026 | marketbeat.comHeron Therapeutics (HRTX) Expected to Announce Quarterly Earnings on TuesdayApril 28, 2026 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of "Hold" from BrokeragesApril 28, 2026 | marketbeat.comHeron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026April 27, 2026 | globenewswire.comResearch Analysts Set Expectations for HRTX Q1 EarningsApril 27, 2026 | marketbeat.comHC Wainwright Cuts Earnings Estimates for Heron TherapeuticsApril 24, 2026 | marketbeat.comThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarApril 7, 2026 | zacks.comHeron (HRTX) Q4 2025 Earnings Call TranscriptFebruary 28, 2026 | fool.comHeron Therapeutics, Inc. Q4 2025 Earnings Call SummaryFebruary 27, 2026 | finance.yahoo.comHeron Therapeutics Inc (HRTX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...February 26, 2026 | finance.yahoo.comHeron Therapeutics: Q4 Earnings SnapshotFebruary 26, 2026 | wtop.comWHeron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to SayFebruary 26, 2026 | zacks.comHeron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial ResultsFebruary 26, 2026 | globenewswire.comWhy Heron Therapeutics, Inc.’s (HRTX) Stock Is Up 5.50%February 25, 2026 | aaii.comAHeron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026February 17, 2026 | globenewswire.comHeron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue;January 9, 2026 | caledonianrecord.comCHeron Therapeutics stock soars after strong Q4 revenue growthJanuary 9, 2026 | uk.investing.comHeron rises as preliminary revenue figures exceed estimatesJanuary 9, 2026 | msn.comWhy Heron Therapeutics, Inc.’s (HRTX) Stock Is Up 10.63%January 9, 2026 | aaii.comAHeron Therapeutics Reports Preliminary Fourth Quarter and Full-Year 2025 Financial ResultsJanuary 9, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHRTX and AUPH Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$16.04 +0.27 (+1.71%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$15.02 -1.02 (-6.35%) As of 04:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Heron Therapeutics NASDAQ:HRTX$1.23 +0.01 (+0.82%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$1.21 -0.02 (-1.30%) As of 04:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
